Press release
Oncolytic Virus Immunotherapy Market will surpass US$ 214 Mn revenues towards the end of 2029
Oncolytic Virus Immunotherapy Market 2022
The global Oncolytic Virus Immunotherapy Market is expected to grow on an impertinent note in the next 10 years. It could witness a CAGR of 12% and reach US$ 214 Mn by 2029. Data processing through Big Data is on the anvil. Clinical software solutions are there to help out, taking the help of Big Data. Thus, data accumulation as well as analytics would be there in a precise manner. This would be the probable facts with healthcare vertical in future.
The new study report by Persistence Market Research (PMR) reveals that the oncolytic virus immunotherapy market value is all set to reach US$ ~67 Mn, by 2019-end. As per the PMR's report, the oncolytic virus immunotherapy market is estimated to grow at a CAGR of ~12% over the period of assessment, 2019-2029.
Get Free Sample Copy of this Report@ https://www.persistencemarketresearch.com/samples/15262
Increasing adoption of adjuvant therapy in developed economies has been fueling the demand for new treatments such as oncolytic virus immunotherapy. For instance, the launch of first FDA approved oncolytic virus, IMLYGIC™ (talimogene laherparepvec) by the leading pharmaceutical manufacturer Amgen has offered oncologists and patients a wider and more targeted treatment approach for overcoming cancer. Amgen's IMLYGIC™ remains the only FDA approved oncolytic virus immunotherapy drug that is prescribed for melanoma cancer.
Favorable reimbursement for oncolytic virus immunotherapy is poised to offer new growth opportunities for the market players. Additionally, Affordable Care Act in the U.S. is paving the way for successfully increasing insurance coverage for cancer treatment, and the result is likely to lead to increased demand for oncological therapies. Such factor along with several favorable policies for cancer treatment is anticipated to contribute immensely towards the growth of the oncolytic virus immunotherapy industry during the forecast period.
Company Profiles:
BioVex, Inc. (Amgen, Inc.)
Cold Genesys, Inc.
DNAtrix Therapeutics
Genelux Corporation
Lokon Pharma AB
Oncolytics Biotech, Inc.
ORYX GmbH & Co. KG
PsiOxus Therapeutics
SillaJen, Inc.
Sorrento Therapeutics, Inc.
Takara Bio
Targovax ASA
Transgene sa
Turnstone Biologics
VCN Biosciences
Viralytics Ltd. (Merck & Co., Inc.)
Vyriad
Shanghai Sunway Biotech
Growing Prevalence of Metastatic Cancer Bringing in Massive Competition in the Oncolytic Virus Immunotherapy Landscape
According to PMR, growing prevalence of metastatic cancer and rising demand for adjuvant therapy drugs and cancer relapses during cancer treatment have created opportunities for key market players to come up with oncolytic virus immunotherapy products at competitive rates by combining new viruses. Apart from the top global market players such as BioVex, Inc. (Amgen, Inc.) and Shanghai Sunway Biotech Co. Ltd. (China), there are several other players in the regional oncolytic virus immunotherapy market that are constantly focusing on discovering new drug candidates in oncolytic virus immunotherapy.
Most of the drugs in the pipeline are in various stages of clinical trials awaiting market approvals. For example, oncolytic viruses from Transgene/Sillajen, Oncolytic Biotech and other players are in the late phase III stage of clinical trials, and are expected to enter the oncolytic virus immunotherapy market in the coming years.
According to the PMR's report, the adoption of oncolytic virus immunotherapy in hospitals will continue to account for relatively high market share, while stakeholders are targeted towards capitalizing on specialty clinics. A significant rise in demand for oncolytic virus immunotherapy drugs in developed countries will further work to the advantage of the market players.
Request for Methodology@ https://www.persistencemarketresearch.com/methodology/15262
A remarkable shift has been observed in the new drug development and product launch in cancer treatment drugs as the blockbuster drug model is dead. Key players are now adopting new strategies to develop adjuvant therapies and supportive therapies that can help irradiate cancer at the maximum level, such as oncolytic virus immunotherapy combined with chemotherapy. Such developmental trends are likely to remain instrumental to the growth of the oncolytic virus immunotherapy market.
Increasing Immunotherapy Research Will Offer New Growth Prospects
According to the PMR study, increasing importance of R&D in oncology medicines and immunotherapies for cancers such as colorectal, lung, multiple myeloma, prostate, and melanoma is expected to create immense growth opportunities for the oncolytic virus immunotherapy market.
Besides this, collaborations among the key players in the pharmaceutical industry, funding programs and reimbursement policies to meet the unmet diagnostic and treatment needs of the patients suffering from life-threatening diseases such as cancer are also expected to fuel the growth of the oncolytic virus immunotherapy market.
Growing interest of biopharmaceutical industries in the development of biologics for various cancers, will further expand the pipeline for the treatment of cancer. Various major players are concentrating on the research for the available treatment and development of specific oncolytic virus for cancer, which will boost the market for oncolytic virus immunotherapy during the forecast period. Further, growing acceptance of oncolytic drugs among patient pool is also high due to treatment effectiveness of the medication. Hence, companies operating in oncolytic virus immunotherapy are expected to mostly derive profit from the development of adoptive immune viruses.
The funding for cancer research and investments in cancer therapy and oncolytic virus immunotherapy have increased, which has increased the number of personnel employed and projects undertaken. The major sources of research and development spending include governments, private funding, venture capitalists or commercial organizations.
Business analysts from PMR also demonstrate groundbreaking views on the development of the oncolytic virus immunotherapy market along with insights on key business approaches and policies by competitors in the oncolytic virus immunotherapy business.
Access Full Report@ https://www.persistencemarketresearch.com/checkout/15262
Key Questions Answered in the Oncolytic Virus Immunotherapy Market Report
How is the Oncolytic Virus Immunotherapy Market expected to grow over the projected period?
What direction is the Oncolytic Virus Immunotherapy Market expected to take in terms of volume and value during the forecast period?
What is the impact of macroeconomic factors on the Oncolytic Virus Immunotherapy Market in future?
What are the key market drivers in the Oncolytic Virus Immunotherapy Market?
What are significant opportunities and improvement areas for Oncolytic Virus Immunotherapy Market manufacturers?
What are the key developments and trends taking over the Oncolytic Virus Immunotherapy Market?
Which are the emerging countries that are expected to create significant growth opportunities in the Oncolytic Virus Immunotherapy Market?
If you have any special requirements, please let us know and we will offer you the report as you want and also We Provide you Table of Content.
Access Related Reports-
Ischemic Optic Neuropathy Treatment Market- https://www.persistencemarketresearch.com/market-research/ischemic-optic-neuropathy-treatment-market.asp
Neuroscience Market- https://www.persistencemarketresearch.com/market-research/neuroscience-market.asp
Contact Us:
Persistence Market Research
Address - 305 Broadway, 7th Floor, New York City, NY 10007 United States
U.S. Ph. - +1-646-568-7751
USA-Canada Toll-free - +1 800-961-0353
Sales - sales@persistencemarketresearch.com
About Us:
PersistenceMarketResearch is an esteemed company with a reputation of serving clients across domains of information technology (IT), healthcare, and chemicals. Our analysts undertake painstaking primary and secondary research to provide a seamless report with a 360 degree perspective. Data is compared against rep/uted organizations, trustworthy databases, and international surveys for producing impeccable reports backed with graphical and statistical information.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Oncolytic Virus Immunotherapy Market will surpass US$ 214 Mn revenues towards the end of 2029 here
News-ID: 2633922 • Views: …
More Releases from Persistence Market Research
Nanomaterials Market Valued at US$ 22.1 Billion in 2025, Poised to Reach US$ 69. …
The nanomaterials market has entered a phase of accelerated commercialization, driven by technological maturity and growing demand across sectors. The market's rapid expansion is supported by rising investments in research and development, improved synthesis techniques, and the ability to mass-produce high-quality nanomaterials at reduced costs.
Get a Sample PDF Brochure of the Report (Use Corporate Email ID for a Quick Response): https://www.persistencemarketresearch.com/samples/33646
By 2025, the market will reach an estimated valuation of…
Mycotoxin Testing Market Value to Reach US$ 3,268.6 Mn by 2032 Driven by Food Sa …
The global mycotoxin testing market is witnessing robust growth, driven by the increasing need for food safety and quality assurance across agricultural and food production sectors. Valued at US$ 2,145.3 million in 2025, the market is projected to reach approximately US$ 3,268.6 million by 2032, expanding at a steady compound annual growth rate (CAGR) of 6.2% during the forecast period (2025-2032). This growth is primarily attributed to the rising awareness…
Natural Health Supplements Market to Reach $112.8 Bn by 2032 Driven by Wellness …
The global natural health supplements market is set for robust expansion, reflecting the world's growing inclination toward wellness, preventive healthcare, and clean-label nutritional products. The market is projected to reach a valuation of US$ 66.7 billion in 2025 and is expected to exhibit a healthy compound annual growth rate (CAGR) of 7.8% during the forecast period from 2025 to 2032. By the end of 2032, the market is anticipated to…
Pet Snacks and Treats Market Value to Reach $19.5 Bn by 2030 Driven by Rising Pe …
The global pet snacks and treats market is poised for notable growth over the coming years, expanding from a valuation of US$13.3 billion in 2023 to an estimated US$19.5 billion by the end of 2030. The market is forecast to grow at a compound annual growth rate (CAGR) of 5.6% during the period from 2023 to 2030. This consistent growth trajectory is primarily attributed to rising pet ownership rates, increasing…
More Releases for Oncolytic
Prominent Oncolytic Virus Therapy Market Trend for 2025: Accelerating Oncolytic …
Which drivers are expected to have the greatest impact on the over the oncolytic virus therapy market's growth?
The rise in cancer incidences is likely to fuel the expansion of the oncolytic virus therapy market. Oncolytic virus therapy is gaining traction as an appealing approach to treating cancer- a collection of diseases marked by abnormal cell growth and proliferation. This therapeutic strategy effectively targets and eliminates cancer cells, while also triggering…
Enhancing the Immune Response with Oncolytic Virus Therapy
Oncolytic virus therapy is revolutionizing cancer treatment by harnessing the unique characteristics of viruses to specifically target and destroy cancer cells. This cutting-edge approach represents a significant advancement in cancer care, offering renewed hope for patients with different types of cancer.
Download Report:
https://www.kuickresearch.com/report-oncolytic-virus-immunotherapy-market-oncolytic-virus-therapy-market-oncolytic-virus-fda-approved-oncolytic-virus-clinical-trilas
The essence of oncolytic virus therapy is based on genetically modified viruses that can selectively attack and kill cancer cells while leaving healthy tissue unharmed. These engineered viruses take…
Creative Biolabs Unleashes Solutions to Validate Oncolytic Virotherapy
Creative Biolabs introduces safety and efficacy validation strategies for oncolytic virotherapy.
New York, USA - June 17, 2024 - Oncolytic virotherapy appears as a new paradigm in cancer immunotherapy that enrolls specifically engineered viruses to selectively infect and kill cancer cells, some of which have marched into clinical trials, like adenoviruses, HSV, reovirus, vaccinia virus, and measles. With so many other candidates still on their preclinical journey, the requests to validate…
Oncolytic Virus Competitive Landscape 2023 (Updated)
DelveInsight's, "Oncolytic Virus Competitive Landscape 2023" report provides comprehensive insights about 150+ Oncolytic Virus Companies and 175+ drugs in the Oncolytic Virus Competitive landscape. It covers the Oncolytic Virus therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Oncolytic Virus Competitive Landscape Report
• DelveInsight's Oncolytic Virus report depicts a robust space with 150+ Oncolytic…
Oncolytic Virus Therapy Market Oncolytic Virus Therapy Clinical Pipeline Report …
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
Prologue to Oncolytic Virus
1.1 Outline of Oncolytic Virotherapy
1.2 Trail from Genesis to Biogenetics
Primer of Virotherapy in Malignancies
2.1 Oncolytic Viruses towards Cancer
2.2 Approaches for Targeting Tumor Cells
2.2.1 Pro Apoptotic Targeting
2.2.2 Translational Targeting
2.2.3 Transcriptional Targeting
2.2.4 Transductional Targeting
Mechanism…
Global Oncolytic Virus Therapy Report Highlight Market Opportunity & Insight On …
“Global Oncolytic Virus Therapy Market and Pipeline Outlook 2022” report analyzes ongoing clinical and non-clinical trends in the oncolytic virus therapy market. Currently there are 2 oncolytic virus therapies commercially available in the market. This report analyzes the ongoing clinical trial of 48 oncolytic virus therapies in clinical pipeline and gives comprehensive clinical insight on various parameters associated with the development of the oncolytic virus therapies. Most of the oncolytic…
